Molecular Health and CENTOGENE Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs

Newsroom

All news

CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs 

 

  • The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy.
  • Real-life data and Innovative Bioinformatic Algorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new orphan drugs for many diseases and disease areas.
  • RIBA develops and offers data-/computing-driven solutions to guide the highest and most precise innovation for a new way of drug development in a modern biopharmaceutical environment.
  • The collaboration will start with Epilepsy as the first indication

Cambridge, MA, USA & Rostock/Berlin, Germany, and Heidelberg, Germany, July 20, 2020 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Molecular Health, a leading company in the field of data and computing science for precision medicine, announced today that they will collaborate exclusively to initiate the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project – starting with Epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based on the combination of large real-life data sets in rare disease with innovative big data, innovative artificial intelligence, as well as computational algorithms and expertise. Both companies are convinced that this strategy of merging real-life data with a global curated biomedical knowledge, as well as applying artificial intelligence and scientific computing will radically change and transform biomedical research, product development, and therapy. Additionally, it will offer data-/computing-driven solutions to guide the highest and most precise innovation for the new way of drug development in a modern biopharmaceutical environment.

 

Prof. Arndt Rolfs, CENTOGENE Chief Executive Officer, stated, “We are excited about this collaboration. Both companies have been analyzing the potential interaction for an extended period of time and are deeply convinced that now is the right time to start an exclusive cooperation focusing on rare genetic diseases. The complementary expertise and knowledge of both companies will allow us to reduce the time to develop a new orphan drug by combining of real-life data and innovative computational biomedical expertise. CentoMD®, one of the world’s largest rare disease data repositories, allows us to take advantage of the high quality of the real-life data from a global cohort of more than 500,000 consented patients. The extraordinary expertise of Molecular Health will not only speed up the identification of new targets in rare disease, but also allow us to de-risk and accelerate the development of new orphan drugs.

 

“By starting this exciting collaboration between our companies, we are initiating and building a unique novel model of personalized healthcare. The combination of both companies’ data and expertise will ultimately transform modern drug development and therapy. It will allow for the development of better drugs with higher specificity and safety, lower attrition rates in clinical studies, and a faster time to market to help patients with severe diseases worldwide through novel therapies,” said Dr. Friedrich von Bohlen, Molecular Health Chief Executive Officer. “Together with CENTOGENE, Molecular Health´s deep scientific, medical, and computational expertise will lay the fundament for personalized healthcare options in rare diseases to fulfill the promise of precision medicine.”

 

The companies have agreed to start with Epilepsy as the first indication. Financial details were not disclosed.

 

Leveraging predictive analytics to estimate clinical trial success

Newsroom

All news

Leveraging predictive analytics to estimate clinical trial success

Estimation of the success likelihood of a clinical trial plays a vital role in determining the time and investment it takes to bring efficacious drug treatment to patients to cure and manage disease. 

 

In an interview with CIO Applications, a Silicon Valley-based tech magazine, Blanca Baez, SVP, Global Head of Pharma & Biotech, and Armin Schneider, SVP of Scientific & Medical Affairs of Molecular Health, share their insights on how the company helps in making unbiased evidence-based clinical development and portfolio  decisions with its technology platform branded MH Predict, by converting clinical and molecular data and medical knowledge into actionable information. Read more at: https://www.molecularhealth.com/wp-content/uploads/2020/05/MH_Predict_Interview_CIO_Applications_6-2020.pdf

Important COVID-19 Update from Molecular Health

Newsroom

All news

Important COVID-19 Update from Molecular Health

Dear customers and partners,

 

at Molecular Health we share the global concern over the coronavirus pandemic. We want to assure you that we will maintain uninterrupted operation during these challenging times.

 

Our principal investor is Dievini, the investment company of Dietmap Hopp, focusing on innovative biotechnological products and technologies. Also in Dievini’s investment portfolio is the Tübingen-based company CureVac AG, currently in the news as they ramp up their efforts to develop an mRNA-based coronavirus vaccine.

 

Molecular Health’s software identifies the best drugs for individual cancer patients, and our customers – hospitals, laboratories, and patients – depend on us to continue to provide high-quality interpretation of tumours, because, especially now, all patients are entitled to the best healthcare possible.

Our software also enables pharmaceutical companies to improve their research and design more effective clinical trials.

 

In these times of massive transformation, we at Molecular Health have adapted our processes to protect our staff, our partners, and especially those in risk groups:

  • We are keeping our team safe: all our employees are working from home office.
  • We strongly support social distancing: all business meetings with customers and partners are now held virtually. Reach out to your contact person at Molecular Health if you have any questions about an upcoming appointment.
  • We are prepared: if any of our employees should become ill, we will do whatever it takes to remain productive and deliver our services seamlessly.

Thank you for your continued partnership, and please don’t hesitate to contact us if you have any questions or concerns.

 

With kind regards from Heidelberg,

Dr. Friedrich von Bohlen

CEO

Request whitepaper on Tumor Mutational Burden (TMB)

Newsroom

All news

Whitepaper: Tumor Mutational Burden (TMB)

The Tumor Mutational Burden (TMB) is a biomarker that shows the total number of somatic and coding mutations, base substitutions, insertions or measures deletions (indels) per megabase (Mb) of the examined genome. It must be validated individually for each indication. Strongly mutated tumors are more likely to generate neoantigens that are recognized as foreign by immune cells. Tumors with a high TMB can therefore have a high immunogenicity. Read more about why TMB is relevant in the context of cancer immunotherapy in our whitepaper: https://www.molecularhealth.com/us/tumor-mutational-burden-us/

Molecular Health is featured in DrugBank case study on data-driven technologies

Newsroom

All news

Molecular Health is featured in DrugBank case study on data-driven technologies

Molecular Health is featured in a case study of DrugBank, the world’s largest online database of drug and drug target information. DrugBank is a widely used data source for companies working in the pharmaceutical, healthcare, and technology space. The data integrates seamlessly into in-house products to enhance outcomes for data-driven decision making. Read more at: DrugBank case study

Molecular Health – Transforming Cancer Treatment to Improve Patient Lives

Newsroom

All news

Molecular Health – Transforming Cancer Treatment to Improve Patient Lives

Each cancer diagnosis is unique, so individualized treatment is critical. With its Molecular Health Guide (MH Guide) powered by SAP HANA®,

Molecular Health is transforming cancer treatment. The solution mines and analyzes a wealth of data on each patient, their cancer, and relevant medical

data to help oncologists quickly identify the most promising therapies. By advancing personalized, evidence-based medicine, Molecular Health is transforming cancer treatment to help improve.

 

https://www.molecularhealth.com/wp-content/uploads/2020/01/SAP-Story-about-MH-Guide.pdf